Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient

DOI Web Site PubMed

Bibliographic Information

Other Title
  • レナリドミド・デキサメタゾン治療により血液透析から離脱し得た難治性BJP型骨髄腫
  • 症例報告 第3回日本血液学会関東甲信越地方会 優秀演題 レナリドミド・デキサメタゾン治療により血液透析から離脱し得た難治性BJP型骨髄腫
  • ショウレイ ホウコク ダイ3カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ユウシュウ エンダイ レナリドミド ・ デキサメタゾン チリョウ ニ ヨリ ケツエキ トウセキ カラ リダツ シエタ ナンチセイ BJPガタ コツズイシュ

Search this article

Abstract

A 63-year-old man with Bence Jones-κ multiple myeloma (MM) presented with renal impairment. First, we administered a bortezomib-containing regimen which is considered to be the first choice among therapeutic approaches for MM patients with renal failure. However, his condition was refractory to bortezomib, and the renal dysfunction worsened (creatinine 12.55mg/dl) necessitating the initiation of hemodialysis. Subsequently, we administered an adjusted dose of lenalidomide and dexamethasone. Dialysis could be discontinued after 3 cycles of lenalidomide therapy. After 4 cycles, he achieved a stringent complete response (sCR) with the creatinine level at 1.85mg/dl. This case suggests lenalidomide to be an effective drug for patients with multiple myeloma and renal impairment refractory to treatment with bortezomib.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 57 (5), 613-617, 2016

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top